Michael L. Maitland

Oncology

8081 Innovation Park Dr
Fairfax, VA 22031

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 03, 2025

Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities.

Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities.

Journal: Cancer research communications

Published: December 17, 2024

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.

Journal: The New England journal of medicine

Published: January 31, 2024

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.

Journal: ESMO open

Published: October 24, 2023

Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.

Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 13, 2023

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.

Journal: JCO precision oncology

Published: April 07, 2023

Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.

Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.

Journal: CPT: pharmacometrics & systems pharmacology

Published: November 19, 2022

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 10, 2022

Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and metabolic syndrome.

Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and metabolic syndrome.

Journal: Molecular metabolism

Published: August 06, 2022

Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension.

Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension.

Journal: Pharmacogenetics and genomics

Published: April 06, 2022

Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.

Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.

Journal: JAMA oncology

Published: January 20, 2022

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply.

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply.

Journal: The New England journal of medicine

Published: October 27, 2021

Showing 1-12 of 62

Last Updated: 09/26/2026